ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

Slides:

Advertisements

Similar presentations

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Advertisements

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

Central blood pressure: what do we really know today?

LEADER trial: Primary Outcome

The Anglo Scandinavian Cardiac Outcomes Trial

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Relative risk of major events with atenolol vs placebo

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Masashi Maeda et al. Heart Asia 2013;5:7-14

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care tests to guide prescription of antibiotics.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Venn diagram of patients with paired pre-cardiac resynchronisation therapy (CRT) and post-CRT echocardiograms. Venn diagram of patients with paired pre-cardiac.

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

The amplitude of oscillation of end-tidal CO2 correlates to the amplitude of oscillation of cardiac output for both patients with heart failure (no fill)

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Reduction of cardiac enzyme release by ischaemic postconditioning (PostC), adjusted on the area at risk (AAR). Reduction of cardiac enzyme release by ischaemic.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Assessment of infarct size by biomarker measurement.

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Left atrial appendage flow during atrial fibrillation, as determined by pulsed Doppler during transoesophageal echocardiography. Left atrial appendage.

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide therapy.37 ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CV, cardiovascular; RRR, relative risk reduct... ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide therapy.37 ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CV, cardiovascular; RRR, relative risk reduction. Hassan Fares et al. Open Heart 2016;3:e000473 ©2016 by British Cardiovascular Society